Abstract
In this bi-institutional study, twenty-three stage IIIC-IV MAGE-A3+ melanoma patients were vaccinated with M3TK-GML biweekly at three dose levels, with a subsequent phase of vaccinations at the maximum dose level. Anti-MAGE-A3 and anti-TK T cells were as-sessed by in vitro assay and delayed-type hypersensitivity skin testing.
Original language | English |
---|---|
Pages (from-to) | 329-330 |
Number of pages | 2 |
Journal | Journal of Cancer |
Volume | 2 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2011 |
Keywords
- Immunotherapy
- MAGE-A3
- Melanoma
ASJC Scopus subject areas
- Oncology